Prognosis Research: A Strategic Initiative in Translational Pathways (PROGRESS)

战略重要性临床调查的一种基本形式涉及在一个时间点描述患有疾病或疾病的人的特征，并跟踪他们，看看他们是否以及为什么在另一个时间点取得进展。这样的预后研究是重要的了解如何？翻译？改善健康的新方法，从最初的发现，通过评估阶段，并在适当时进入临床实践。预后研究应补充和增加价值MRC的战略目标，涉及：遗传学，生物标志物，健康，健康记录和基于人口的数据和转化研究的开发。但是，不同疾病领域的大量系统评价表明，预后研究的承诺与其交付能力之间存在差距。作为对这一点的回应，我们已经开发了一个即将推出的系列6篇文章在BMJ/PloSMed，其中规定了一个框架的预后研究，并提出建议。目的：PROGRESS合作伙伴关系的目的是批判性地开发和系统地应用概念，方法和建议（从最初的PROGRESS文章系列和其他地方）跨越不同的疾病领域，以提高预后研究的转化影响。我们将通过建立一个新的翻译预后研究国际联盟来实现这一目标。该伙伴关系的研究人员（来自6篇文章系列的作者）目前领导着6600万美元的预后研究资金。在医学研究理事会的支持下，将在疾病领域和方法学科建立国际伙伴关系。伙伴关系工作流程伙伴关系将提供三个相互关联、具有里程碑意义的工作流程：一.通过有针对性的讲习班，我们寻求开展扶持活动，以（a）推进分层医学的方法开发，寻求针对受益最大的患者进行治疗（B）提高开放性（？透明度？）（c）确定在临床队列中进行更好研究的机会;（d）传播伙伴关系的研究结果（知识转让）。II新的研究我们将进行新的研究，重点是预后研究在我们的合作伙伴关系中的重要性。我们将回顾已发表的文献（知识综合），并在我们自己的临床队列中进行新的分析。其中包括为50，000多名患有不同疾病的患者提供新的机会：冠状动脉疾病;癌症;创伤和分娩中的急性严重出血以及肌肉骨骼疾病。III培训我们将开发一系列教学课程，更高的学位和奖学金机会，以培养未来的国家和国际预后研究领导者。

Strategic importance A basic form of clinical enquiry involves characterising people with disease or illness at one time point and following them up to see whether and why they have progressed at another time point. Such prognosis research is important in understanding how to ?translate? new approaches to improving health from initial discovery, through phases of evaluation and, where appropriate, into clinical practice. Prognosis research should complement and add value to MRC strategic aims, relating to: genetics, biomarkers, wellbeing, exploitation of health records and population based data and translational research. But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations. Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research. Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66 million. With MRC support the international Partnership will be established across disease areas and methodological disciplines. Partnership workstreams The Partnership will deliver three inter-related, milestone-driven workstreams: I Enabling activities, through targeted workshops we seek to (a) advance methods development in stratified medicine, which seeks to target treatments at those patients who will benefit the most (b) improve the openness (?transparency?) with which prognosis research is reported in scientific papers, (c) identify opportunities for better research across clinical cohorts and (d) disseminate Partnership findings (knowledge transfer). II New research We will do new research, focussing on examples of where prognosis research is important in translation across our Partnership. We will both look backwards at published literature (knowledge synthesis) and forwards carrying out new analyses in our own clinical cohorts. These include novel opportunities in over 50,000 patients with different diseases: coronary disease; cancer, acute severe bleeding in trauma and childbirth and musculoskeletal disorders. III Training We will develop a range of taught course, higher degree and Fellowship opportunities to develop future national and international leaders in prognosis research.